On 12 January 2017, orphan designation (EU/3/16/1820) was granted by the European Commission to Centre Hospitalier Universitaire d'Angers, France, for hydroxychloroquine for the treatment of antiphospholipid syndrome.
The sponsorship was transferred to Crisitina Belizna, France, in November 2020.
|Disease / condition||
Treatment of antiphospholipid syndrome
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.